Stock EVFM EVOFEM BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Evofem Biosciences, Inc.

Equities

EVFM

US30048L3024

Market Closed - OTC Markets
Other stock markets
 15:59:32 2024-05-10 EDT 		5-day change 1st Jan Change
0.0136 USD -14.47% Intraday chart for Evofem Biosciences, Inc. +13.33% -78.75%
03-27 Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-27 Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
PR
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
PR
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
PR
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
AQ
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
PR
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
BU
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi, the First and Only FDA-Approved Hormone-Free Contraceptive Gel
AQ
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
PR
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders
BU
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
PR
Evofem Biosciences : Presentation
PU
OTC Stocks News-Based Catalyst Watchlist (IMRFF, BLFR, NILIF, EVFM)
AQ
Evofem Biosciences : EVFM at a Glance
PU
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
PR
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi until Evofem's Phexxi Patents Expire
AQ
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
PR
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
PR
Evofem Biosciences' : Proxy for 14 September 2023 Annual Meeting of Stockholders
PU
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EVFM Stock
  4. News Evofem Biosciences, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW